[DERM] Dermira, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 30.57 Change: 0.63 (2.1%)
Ext. hours: Change: 0 (0%)

chart DERM

Refresh chart

Strongest Trends Summary For DERM

DERM is in the medium-term down -26% below S&P in 3 months and up 47% in 6 months. In the long-term down -76% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company?s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinical development include DRM02, an inhibitor of phosphodiesterase-4 for the treatment of inflammatory skin diseases; and DRM05, a photodynamic therapy for the treatment of acne. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-17.27% ROE-20.31% ROI
Current Ratio10.38 Quick Ratio Long Term Debt/Equity0.02 Debt Ratio0.09
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities40 K Cash From Investing Activities1.86 M Cash From Operating Activities-5.12 M Gross Profit
Net Profit-14.04 M Operating Profit-14.23 M Total Assets165.61 M Total Current Assets124.49 M
Total Current Liabilities12 M Total Debt1.94 M Total Liabilities24.75 M Total Revenue
Technical Data
High 52 week14.82 Low 52 week6.19 Last close11.7 Last change1.21%
RSI26.07 Average true range0.83 Beta1.06 Volume98.87 K
Simple moving average 20 days-6.39% Simple moving average 50 days7.76% Simple moving average 200 days16.19%
Performance Data
Performance Week4.93% Performance Month-11.23% Performance Quart80.83% Performance Half-1.1%
Performance Year32.35% Performance Year-to-date62.73% Volatility daily4.42% Volatility weekly9.89%
Volatility monthly20.27% Volatility yearly70.22% Relative Volume231.19% Average Volume2.11 M
New High New Low

News

2019-06-11 16:00:00 | Dermira to Present at the Raymond James Life Sciences and MedTech Conference

2019-06-11 08:05:48 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-06-10 08:05:02 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-06-06 13:34:00 | Dermira Advances on Analyst Upgrade to Buy

2019-06-06 08:05:15 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-06-04 08:03:27 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-05-08 15:24:17 | Dermira DERM Q1 2019 Earnings Call Transcript

2019-05-08 11:13:10 | Did You Manage To Avoid Dermira's NASDAQ:DERM Painful 63% Share Price Drop?

2019-05-08 01:11:11 | Edited Transcript of DERM earnings conference call or presentation 7-May-19 8:30pm GMT

2019-05-07 19:25:11 | Dermira DERM Reports Q1 Loss, Lags Revenue Estimates

2019-05-07 18:19:15 | Dermira: 1Q Earnings Snapshot

2019-05-07 16:05:00 | Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update

2019-05-07 08:03:19 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-04-30 16:05:00 | Dermira to Report First Quarter 2019 Results and Host Conference Call on Tuesday, May 7, 2019

2019-04-25 10:34:02 | Dermira DERM May Report Negative Earnings: Know the Trend Ahead of Q1 Release

2019-04-17 09:15:01 | NASDAQ Back Above 8,000

2019-04-08 17:06:00 | Here's Why Dermira Shot Up 62% in March

2019-04-03 16:05:00 | Dermira to Present at the 18th Annual Needham Healthcare Conference

2019-04-01 14:09:21 | Does The Dermira, Inc. NASDAQ:DERM Share Price Fall With The Market?

2019-03-28 08:02:07 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-03-26 08:21:58 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-03-25 00:00:00 | Dermira Announces “Life Unfolds” Direct-to-Consumer Campaign to Highlight QBREXZA™ glycopyrronium Cloth

2019-03-22 16:01:00 | Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2019-03-20 10:28:02 | Dermira DERM Catches Eye: Stock Jumps 12%

2019-03-19 19:36:06 | Dermira Prices $130.0 Million Public Offering of Common Stock

2019-03-19 16:00:00 | Why Dermira Stock Jumped Again Today

2019-03-19 10:52:02 | Company News For Mar 19, 2019

2019-03-19 08:31:14 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-03-19 06:06:00 | Can Dermira Stock Keep Soaring?

2019-03-18 16:30:24 | Dermira Announces Proposed Public Offering of Common Stock

2019-03-18 14:22:58 | Why Dermira Stock Is Soaring More than 80% Today

2019-03-18 12:48:21 | Stocks making the biggest moves midday: Facebook, Deutsche Bank, Lumber Liquidators & more

2019-03-18 12:31:42 | Dermira News: Why DERM Stock Is Skyrocketing Today

2019-03-18 12:14:00 | Why Dermira's Shares Are Doubling Today

2019-03-18 11:15:37 | Dermira Investors Get 100% One-Day Payoff a Year After Acne Flop

2019-03-18 10:00:00 | Dermira Shares Rocket After Successful Phase II Eczema Treatment Study

2019-03-18 09:53:04 | Why Dermira Shares Are Shooting Higher After Last Year's Disappointment

2019-03-18 07:24:00 | Dermira shares soar 83% premarket on news of positive trial of dermatitis treatment

2019-03-18 07:00:00 | Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis

2019-03-12 10:28:35 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-03-06 08:05:03 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-03-05 16:00:00 | Dermira to Present at the Cowen and Company 39th Annual Health Care Conference

2019-03-05 08:03:56 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-03-01 08:51:01 | Implied Volatility Surging for Dermira DERM Stock Options

2019-03-01 08:00:00 | Dermira Presents New Data from its Phase 3 Clinical Program Evaluating Glycopyrronium Tosylate QBREXZA™ glycopyrronium cloth in Patients with Primary Axillary Hyperhidrosis

2019-02-27 03:05:49 | Edited Transcript of DERM earnings conference call or presentation 26-Feb-19 9:30pm GMT

2019-02-26 16:01:00 | Dermira Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

2019-02-26 14:30:00 | Dermira Inc to Host Earnings Call

2019-02-26 08:00:00 | Dermira to Present New Analyses of the Glycopyrronium Tosylate Clinical Program at the 77th American Academy of Dermatology Annual Meeting

2019-02-22 08:00:00 | Dermira Initiates Proof-of-Concept Study to Evaluate QBREXZA™ glycopyrronium Cloth in Patients with Primary Palmar Hyperhidrosis